Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Up 823.5% in August

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 584,609 shares, a growth of 823.5% from the July 30th total of 63,307 shares. Approximately 9.0% of the shares of the company are sold short. Based on an average trading volume of 38,485,659 shares, the short-interest ratio is currently 0.0 days.

Creative Medical Technology Stock Down 0.4%

NASDAQ CELZ traded down $0.01 during trading hours on Thursday, hitting $1.19. 26,776 shares of the stock were exchanged, compared to its average volume of 3,751,813. The company has a market cap of $7.81 million, a price-to-earnings ratio of -0.57 and a beta of 1.94. Creative Medical Technology has a 12-month low of $0.62 and a 12-month high of $6.25. The stock has a 50-day moving average of $1.14 and a 200 day moving average of $1.75.

Creative Medical Technology (NASDAQ:CELZ) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, equities research analysts expect that Creative Medical Technology will post -1.18 earnings per share for the current year.

Institutional Trading of Creative Medical Technology

A number of institutional investors have recently modified their holdings of CELZ. Seros Financial LLC purchased a new position in Creative Medical Technology in the second quarter worth $53,000. Jane Street Group LLC acquired a new position in shares of Creative Medical Technology during the 4th quarter worth $59,000. Finally, Clear Harbor Asset Management LLC acquired a new position in shares of Creative Medical Technology during the 2nd quarter worth $192,000. 1.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Weiss Ratings raised Creative Medical Technology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Roth Capital restated a “buy” rating on shares of Creative Medical Technology in a research note on Thursday, August 20th. Finally, Wall Street Zen raised Creative Medical Technology to a “sell” rating in a report on Saturday, August 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Creative Medical Technology currently has an average rating of “Hold”.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.